Clinical Trial

This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an early-stage clinical trial to determine a safe and effective dose for Tivoxavir Marboxil (TRX-100) in patients with mild to moderate Influenza. Participants will take a study drug as well as a standard therapy. A descriptive statistics will be used to present the study results.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-01-19; most recent amendment 2026-03-26.
Status change: Withdrawn → Active, Not Recruiting 2026-02-04
Trial Details
NCT Number NCT07371650
Lead Sponsor Traws Pharma, Inc.
Conditions Influenza
Enrollment 105 participants
Start Date 2025-12-15
Primary Completion 2026-12 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-27